Watch for Zelnorm's Return for Irritable Bowel Syndrome With Constipation

Zelnorm (tegaserod) will be back on the market to treat irritable bowel syndrome with constipation (IBS-C) in women.

It was first approved in 2002...then taken off the market in 2007 due to reports of MI, stroke, and unstable angina.

Since then, it's been available on a case-by-case basis from various manufacturers.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote